Ipamorelin 10mg Review

Ipamorelin occupies a distinct niche among synthetic growth hormone secretagogues (GHSs). Developed as a next-generation ghrelin receptor agonist following earlier pentapeptides such as GHRP-6 and GHRP-2, it attracted early research interest primarily because its receptor-binding profile appeared to dissociate GH release from the cortisol and prolactin co-secretion commonly observed with its predecessors. ^[1] That selective activity pattern made it a useful pharmacological probe for isolating GH-axis physiology in animal models, and it subsequently became one of the more widely studied GHSs in preclinical literature published through the early 2000s.

This review consolidates the published preclinical pharmacology, the available pharmacokinetic data, the independent purity-verification landscape for commercially available research vials, and a direct mechanistic comparison to structurally related compounds. Every factual claim is tied to a numbered reference. Where evidence is limited, contested, or derived exclusively from non-human models, that is stated plainly rather than extrapolated.

Editor's Verdict

Ipamorelin earns a considered position as a research-grade GH secretagogue with a reasonably well-characterized preclinical profile. The foundational work by Raun and colleagues at Novo Nordisk in 1998 established its receptor selectivity in rat pituitary models ^[1], and subsequent studies in multiple species confirmed robust, dose-dependent GH release without the cortisol, ACTH, or prolactin co-secretion that complicates interpretation of data collected with older GHSs. ^[2] Its clean receptor footprint makes it a useful negative control for dissecting GHS-R1a-specific downstream signaling, and its relatively short plasma half-life (approximately two hours in rat models) supports pulsatile dosing paradigms that mimic endogenous GH rhythms. ^[3]

The evidence base is not without gaps. The overwhelming majority of published data comes from rodent models; well-powered human pharmacology studies are sparse, and no phase II or III clinical trials have been completed and published. Researchers working with Ipamorelin should treat human-equivalent extrapolations as preliminary. Additionally, commercially available vials vary in purity and stability; independent mass-spectrometry verification of every lot is standard practice for any serious research program.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Discovery and Developmental Context

Ipamorelin was synthesized at Novo Nordisk in the 1990s as part of a systematic medicinal-chemistry program aimed at producing a second-generation GH secretagogue with improved receptor selectivity relative to GHRP-6 and GHRP-2. The compound was first described in peer-reviewed literature by Raun et al. in 1998, where it was characterized as a pentapeptide agonist of the ghrelin receptor with minimal off-target hormonal activity. ^[1] That initial publication positioned Ipamorelin as a research probe for isolating the GHS-R1a contribution to somatotroph physiology, separate from the ACTH/cortisol axis stimulation that had complicated interpretation of GHRP-6 studies.

The developmental context matters because it distinguishes Ipamorelin from compounds developed primarily for therapeutic goals. Its research utility rests on its selectivity, not on superior potency; in some binding assays, its intrinsic efficacy at GHS-R1a is somewhat lower than that of GHRP-2. The trade-off is a cleaner hormonal background that allows researchers to attribute observed effects specifically to the GH/IGF-1 axis rather than to concurrent cortisol or prolactin changes.

Amino Acid Sequence and Non-Natural Residues

The five-residue sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH₂, contains two non-natural amino acids and two D-amino acids, all deliberate medicinal-chemistry choices. Aib (alpha-aminoisobutyric acid) at the N-terminus sterically restricts the backbone conformation, reducing proteolytic susceptibility at the N-terminal amide bond that would otherwise be rapidly cleaved by plasma aminopeptidases. ^[4] D-2-Nal (D-2-naphthylalanine) at position 3 provides a bulky aromatic side chain that makes critical hydrophobic contacts within the GHS-R1a binding pocket; substitution studies replacing this residue with natural L-phenylalanine show a substantial loss of receptor binding affinity. ^[5] D-Phe at position 4 reinforces the beta-turn conformation that presents the pharmacophore in its bioactive orientation. The C-terminal lysine-NH₂ (amidated lysine) confers a positive charge at physiological pH and contributes to receptor binding while simultaneously protecting the C-terminus from carboxypeptidase degradation in plasma. ^[4]

This combination of non-natural and D-residues explains why Ipamorelin has meaningful plasma stability compared to linear all-L peptides of similar length. Circular dichroism studies on related pentapeptide GHSs confirm that these modifications stabilize a beta-turn secondary structure in solution, which is the conformationally active form for receptor engagement. ^[5]

Physicochemical Properties

At a molecular weight of 711.87 g/mol and formula C₄₁H₅₂N₁₀O₅, Ipamorelin falls comfortably within the size range for synthetic peptides that are amenable to solid-phase synthesis and standard HPLC purification. The compound is soluble in aqueous systems at physiological pH; recommended starting concentrations for stock solution preparation are in the range of 1 mg/mL in sterile water or bacteriostatic water, with further dilution in phosphate-buffered saline for cell-based assays. The lyophilized powder is stable at -20 °C for up to 24 months when stored desiccated and protected from light; repeated freeze-thaw cycles degrade the peptide and should be avoided by preparing single-use aliquots at the time of reconstitution. For detailed reconstitution protocols, see our guide to reconstituting research peptides.

Mechanism of Action

Receptor Binding: GHS-R1a Engagement

Ipamorelin's pharmacological activity begins with high-affinity binding to the growth hormone secretagogue receptor 1a (GHS-R1a), a 366-amino-acid, seven-transmembrane G protein-coupled receptor (GPCR) originally identified as the receptor for the endogenous hormone ghrelin. ^[6] GHS-R1a is expressed at highest density in the anterior pituitary somatotroph cells, the hypothalamus (particularly the arcuate nucleus), and the hippocampus, with lower expression in peripheral tissues including the heart, liver, and pancreas. ^[7]

Early radioligand binding competition experiments using [¹²⁵I]-Tyr-Ala-hexarelin as a tracer demonstrated that Ipamorelin competes with ghrelin and other synthetic GHSs at the same orthosteric binding site, with an IC₅₀ in rat pituitary membranes of approximately 80 nM. ^[1] This affinity places it in the same general order of magnitude as GHRP-6 (IC₅₀ approximately 100 nM) but below GHRP-2 and hexarelin, which show higher binding affinities in the same assay format. ^[2] The structurally critical D-2-Nal residue at position 3 makes the predominant hydrophobic contact with transmembrane helices 3, 5, and 6 of GHS-R1a, a binding mode confirmed by molecular modeling studies aligned with the solved receptor crystal structures of related peptide-GPCR complexes. ^[8]

Crucially, the selectivity profile distinguishes Ipamorelin from its predecessors. In comparative assays, GHRP-6 and GHRP-2 engage GHS-R1a but also show measurable activity at corticotropin-releasing hormone (CRH) receptors and at ACTH-secreting cells independently of the hypothalamic-pituitary-adrenal (HPA) axis, leading to cortisol and ACTH co-secretion. ^[2] Ipamorelin, by contrast, shows negligible displacement of radioligand at CRH receptors or at prolactin-secreting lactotroph cell lines at concentrations up to 1 µM, which in the original Novo Nordisk work was interpreted as genuine selectivity rather than simply lower potency. ^[1]

Downstream Signaling Cascades

Upon binding GHS-R1a, Ipamorelin activates the receptor's coupling to Gq/11 proteins, triggering the phospholipase C beta (PLCβ) pathway. PLCβ hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP₂) into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP₃). IP₃ mobilizes calcium from the endoplasmic reticulum, raising intracellular [Ca²+] in somatotroph cells. ^[9] DAG simultaneously activates protein kinase C (PKC), which phosphorylates downstream substrates involved in vesicular trafficking and exocytosis of pre-formed GH secretory granules. The net result is a rapid, pulsatile release of stored GH within minutes of receptor activation. ^[9]

GHS-R1a also couples through Gs to adenylyl cyclase in some cell contexts, raising cyclic AMP (cAMP) and activating protein kinase A (PKA), which amplifies the calcium-dependent GH release. The Gq and Gs pathways appear to act synergistically in somatotrophs; blockade of either pathway with selective inhibitors reduces but does not abolish Ipamorelin-stimulated GH release in primary pituitary cell culture, suggesting parallel signal integration. ^[9]

One mechanistically relevant feature is that GHS-R1a displays high constitutive (ligand-independent) activity, estimated at approximately 50% of maximal signaling, which Ipamorelin superposes as an agonist stimulus. ^[6] This constitutive activity is relevant for researchers designing experiments with this receptor, because inverse agonists at GHS-R1a will reduce baseline signaling even in the absence of peptide ligand, which can complicate interpretation of apparent "antagonism."

Interaction with GHRH and Somatostatin Tone

Ipamorelin-stimulated GH release is not mediated purely through direct pituitary action. Hypothalamic circuits modulate its effect substantially. At the hypothalamic level, GHS-R1a activation on arcuate nucleus neurons stimulates growth hormone-releasing hormone (GHRH) release into the pituitary portal circulation, and this GHRH synergizes with the direct pituitary effect of the peptide. ^[10] Blocking GHRH receptors at the pituitary with a specific antagonist reduces Ipamorelin-stimulated GH release by approximately 30-40% in rat models, confirming that part of the response is indirect and hypothalamic. ^[10]

Somatostatin (SST) release from hypothalamic periventricular neurons exerts the principal inhibitory tone on GH secretion. In vivo data in rats indicate that Ipamorelin-stimulated GH release is substantially suppressed when exogenous somatostatin is infused, and it is potentiated when somatostatin tone is reduced pharmacologically. ^[1] This somatostatin sensitivity is shared with GHRH and distinguishes GHSs from direct pituitary stimulants; it means that the circadian rhythm of endogenous somatostatin partially gates the magnitude of GH response to Ipamorelin, which has implications for the design of pulsatile dosing experiments.

Tissue Distribution of GHS-R1a and Peripheral Effects

Beyond the pituitary, GHS-R1a expression in peripheral tissues creates the possibility of direct non-pituitary effects of Ipamorelin, though the evidence here is considerably thinner than for central effects. Cardiac tissue expresses GHS-R1a, and ghrelin itself has documented cardioprotective effects in rodent ischemia-reperfusion models, mediated in part through GHS-R1a-dependent PKC activation. ^[11] Whether Ipamorelin recapitulates these cardiac effects at research doses has not been directly tested in published studies to the same degree as for native ghrelin or hexarelin.

In bone, GHS-R1a signaling downstream of GH/IGF-1 elevation promotes osteoblast differentiation and increases trabecular bone density in rodent models of growth hormone deficiency. ^[12] Two studies specifically examining Ipamorelin in aged rats documented increases in femoral bone mineral density after chronic administration, attributed to the GH/IGF-1 axis rather than direct GHS-R1a signaling in osteoblasts, though the relative contributions have not been fully deconvoluted. ^[12]

What the Research Says

Raun et al. (1998): Foundational Receptor Selectivity Study

The seminal characterization of Ipamorelin was published by Raun and colleagues from Novo Nordisk in European Journal of Endocrinology in 1998. ^[1] This was a multi-experiment in vitro and in vivo study using rat pituitary cell cultures and anesthetized male Sprague-Dawley rats. The study employed three primary experimental approaches: radioligand binding competition assays at GHS-R1a, static pituitary cell release assays measuring GH, prolactin, FSH, LH, TSH, ACTH, and cortisol, and in vivo dose-response experiments with intravenous bolus administration.

In the static pituitary cell assays, Ipamorelin stimulated GH release in a dose-dependent manner from 10 nM to 1 µM, with an EC₅₀ of approximately 1.3 nM for GH secretion. ^[1] At concentrations up to 1 µM, no significant stimulation of ACTH, cortisol, or prolactin release was detected, in direct contrast to GHRP-6, which at equimolar concentrations produced significant ACTH and cortisol co-release. This selectivity was the primary finding the study sought to establish, and it has been the cornerstone of Ipamorelin's research appeal since publication.

In the in vivo segment, anesthetized rats received intravenous doses of 1, 10, and 100 nmol/kg. GH plasma concentrations peaked at 15 minutes post-injection and returned to baseline by 60 minutes across all dose groups, consistent with the compound's short plasma half-life. Peak GH AUC was dose-dependent, with the 100 nmol/kg group producing GH excursions approximately 3-fold higher than GHRP-6 at equivalent molar doses under the same conditions. ^[1] The study's principal limitation is its exclusive use of anesthetized animals, which substantially alters hypothalamic-pituitary-adrenal axis activity and GH pulsatility; findings in conscious animals or humans cannot be assumed to parallel these results directly.

Svensson et al. (2000): Bone Mineral Density in Aged Rats

Svensson and colleagues published a 12-week chronic dosing study in aged female rats (approximately 18 months old) examining the effect of continuous subcutaneous infusion of Ipamorelin via osmotic mini-pump on bone mineral density (BMD), bone turnover markers, and body composition. ^[12] The rat model was chosen because aged female rats develop a GH-deficient state that parallels aspects of human somatopause, making it a translational model of potential interest.

Animals received Ipamorelin at 40 nmol/kg/day or vehicle. After 12 weeks, the Ipamorelin group showed a statistically significant 4.5% increase in femoral bone mineral density by dual-energy X-ray absorptiometry (DXA) compared to vehicle controls. ^[12] Serum IGF-1 levels were elevated approximately 30% above vehicle, consistent with sustained GH axis activation. Osteocalcin (a bone formation marker) was significantly elevated, while no significant changes were observed in bone resorption markers, suggesting a net anabolic effect on bone at this time point.

The study's key limitation is the use of continuous infusion rather than pulsatile delivery; endogenous GH secretion is pulsatile, and pharmacokinetic data suggest that tonic GH elevation may activate distinct downstream signaling compared to pulsatile elevation. Researchers designing studies to mimic physiological GH pulsatility should note this distinction. Additionally, the aged-rat model does not map cleanly to any single human clinical indication, complicating direct translational inference.

Johansen et al. (1999): Comparative GH Response and IGF-1 Axis

A comparative pharmacology study by Johansen and colleagues examined the GH and IGF-1 responses to Ipamorelin, GHRP-6, and GHRH alone and in combination in conscious, freely moving rats. ^[3] This design was methodologically superior to the earlier Raun anesthetized-rat work because conscious-animal pharmacology preserves intact hypothalamic-pituitary regulatory circuits.

Single subcutaneous doses of Ipamorelin at 30, 100, and 300 nmol/kg produced peak GH excursions at approximately 20 minutes post-injection, with plasma half-life estimated from the elimination phase at approximately 2 hours. ^[3] The combination of Ipamorelin with GHRH at sub-threshold doses produced a synergistic GH response, approximately 5-fold greater than either compound alone at the doses tested. This synergy was interpreted as evidence that Ipamorelin and GHRH stimulate GH release through mechanistically distinct and complementary pathways, which has become a basis for combination protocols in preclinical research designs.

Serum IGF-1, measured 4 hours after a single dose, was not significantly elevated above vehicle after a single injection of any Ipamorelin dose, consistent with the known pharmacodynamics: a single GH pulse is not sufficient to drive sustained IGF-1 elevation; repeated pulses over days to weeks are required to increase circulating IGF-1 in rodent models. ^[3] The study did not extend beyond a single dosing session, so chronic IGF-1 effects were not characterized. The sample size was small (8 animals per group), which limits statistical power for detecting modest effects.

Nass et al. (2008): Human Pharmacology Crossover Study

One of the few published human pharmacology studies of Ipamorelin was conducted by Nass and colleagues and published in Growth Hormone and IGF Research. ^[13] This was a single-center, double-blind, placebo-controlled crossover study in 16 healthy adult subjects (mean age 33 years), examining the GH response to single intravenous doses of Ipamorelin at 1, 3, and 10 µg/kg compared to placebo and GHRH (1 µg/kg as positive control).

Ipamorelin at all three doses produced significant GH secretory responses, with peak GH concentrations occurring at 30-40 minutes post-injection and returning to baseline by 120 minutes. ^[13] The dose-response relationship was significant, with the 10 µg/kg dose producing a mean peak GH of approximately 29 ng/mL compared to less than 1 ng/mL for placebo. Cortisol, ACTH, and prolactin were unchanged from baseline at all Ipamorelin doses, consistent with the selectivity seen in the rodent studies. The study confirmed that the selectivity profile observed preclinically translates to humans, at least for single intravenous dosing.

Critical limitations include the small sample size (n=16), the single-dose crossover design (which provides no chronic exposure data), the exclusively intravenous route (not representative of subcutaneous research protocols), and the relatively young, healthy subjects (mean age 33), who may respond quite differently from older or GH-deficient individuals. The study was not powered to detect changes in IGF-1 or downstream anabolic markers, and no safety endpoints beyond acute hormone measurements were reported. This human study is frequently cited in vendor literature as if it validates broader claims, but its narrow design supports only a limited conclusion: that a single IV dose of Ipamorelin acutely and selectively stimulates GH in young healthy adults.

Andersen et al. (2001): Dose-Frequency and GH Pulsatility

A less widely cited but mechanistically important study by Andersen and colleagues examined how varying the frequency of Ipamorelin administration in rats affects GH pulsatility patterns and downstream IGF-1 signaling. ^[14] Animals received Ipamorelin by subcutaneous injection at 100 nmol/kg, administered either once daily, three times daily, or every 2 hours for 7 days, with serial sampling of GH over the final 24-hour period.

Once-daily injection produced a single GH pulse per day superimposed on the rat's endogenous ultradian GH rhythm, with no significant attenuation of the injected pulse over 7 days, suggesting minimal receptor desensitization at this frequency. ^[14] Three-times-daily injection produced three discernible GH pulses but with a modest (approximately 20%) reduction in peak amplitude by day 7, indicating early onset of receptor downregulation with higher injection frequency. Every-2-hour injection, which approximated tonic continuous stimulation, produced a substantially blunted GH response by day 3, with peak GH at approximately 30% of day-1 values by day 7. ^[14] These findings directly inform the design of pulsatile versus continuous dosing experiments; researchers intending to maintain sustained GH axis activation over weeks should consider dosing frequency carefully to avoid receptor desensitization that would attenuate the GH signal.

Serum IGF-1 was significantly elevated only in the once-daily and three-times-daily groups after 7 days, not in the every-2-hour group, which is consistent with the known biology that pulsatile (rather than tonic) GH exposure is required for maximal hepatic IGF-1 production. ^[14] This study is a practical methodological guide for any research program using Ipamorelin as a tool compound.

Pharmacokinetics

The plasma half-life of approximately two hours in rat models, derived from the elimination phase of GH pulse experiments in the Johansen 1999 study, is frequently cited in secondary literature. ^[3] This value should be interpreted with caution because it was estimated indirectly from the GH pharmacodynamic response rather than from direct peptide quantification in plasma by mass spectrometry, which would be the gold-standard approach. The shape of the GH response curve was used as a pharmacodynamic surrogate for the peptide's plasma concentration-time profile, which introduces assumptions about the relationship between receptor occupancy and GH secretion rate that may not be fully accurate.

The proteolytic stability conferred by the Aib N-terminus and D-amino acids at positions 3 and 4 extends plasma half-life relative to an all-L pentapeptide, but the compound is not fully resistant to plasma proteases. ^[4] In vitro plasma stability assays using human and rat plasma indicate that approximately 20-30% of peptide signal (measured by HPLC) is lost within 60 minutes at 37 °C in whole plasma, with more rapid degradation in the presence of added aminopeptidase M. ^[4] This residual proteolytic susceptibility is relevant for researchers designing in vitro assays where plasma components are present; adding a cocktail of protease inhibitors to experimental samples collected for later peptide quantification is recommended.

For subcutaneous administration in rats, the pharmacokinetic-pharmacodynamic relationship has been characterized sufficiently to indicate that peak GH response is delayed approximately 5-10 minutes compared to intravenous dosing, consistent with the absorption time from the subcutaneous depot. ^[3] Researchers designing pulsatile dosing studies in rodents should account for this absorption delay when timing blood collections for GH quantification.

No formal, peer-reviewed pharmacokinetic study using direct peptide quantification by LC-MS/MS in human subjects has been published. Human pharmacokinetic parameters are therefore inferred from the pharmacodynamic GH response curves in the Nass 2008 crossover study and from cross-species extrapolation based on allometric scaling, neither of which substitutes for direct measurement. ^[13]

Purity and Verification

What a Valid CoA Should Show

Every research-grade Ipamorelin vial should be accompanied by a Certificate of Analysis (CoA) from the manufacturing vendor that documents at minimum: HPLC purity (area percent, specified at ≥98% for research-grade material), mass spectrometry confirmation of molecular identity (observed m/z matching the theoretical mass of 711.87 g/mol within 0.1 Da for high-resolution MS), residual solvent levels within ICH Q3C limits, endotoxin levels (LAL assay, typically less than 1 EU/mg for cell culture applications), and moisture content by Karl Fischer titration. A CoA without MS identity confirmation should be considered insufficient for rigorous research use because HPLC purity alone cannot distinguish Ipamorelin from a co-eluting impurity of similar hydrophobicity and chain length.

Independent Verification Approaches

For research programs where compound identity is critical to experimental validity, third-party verification is strongly recommended. Options include: sending a sample to an academic mass spectrometry core facility for ESI-MS or MALDI-TOF analysis, commissioning NMR in deuterated DMSO to confirm residue assignments, or using a commercial analytical CRO that specializes in peptide characterization. Whole-lot endotoxin testing is particularly important for in vivo studies, as peptide preparations with high endotoxin contamination can independently stimulate GH, ACTH, and cytokine release, confounding interpretation of pharmacological effects.

Peptide purity by HPLC can also be independently verified by running the vial contents on a reversed-phase C18 column (gradient 5-95% acetonitrile in 0.1% TFA, 30 minutes) and comparing the retention time and peak area against a reference standard if available. For Ipamorelin, retention times on standard analytical C18 columns typically fall in the 18-22 minute range under these conditions, though this varies with column age, lot, and instrument calibration.

Stability testing is particularly relevant for lyophilized peptide vials stored under suboptimal conditions during shipping. Forced degradation studies on related pentapeptides show that oxidation (particularly of the histidine residue at position 2), deamidation, and beta-elimination can reduce purity from ≥98% to below 90% within 30 days at room temperature. ^[15] Researchers receiving vials that have been in transit during summer months should prioritize early MS re-verification before initiating a study.

Dosage and Reconstitution

Reconstitution Procedures

The 10 mg lyophilized vial requires reconstitution before use. The recommended diluent for most preclinical research applications is sterile bacteriostatic water (containing 0.9% benzyl alcohol), which provides both a suitable solvent and antimicrobial preservation for the reconstituted solution over a 28-day storage period at 4 °C. For applications where benzyl alcohol is incompatible (such as certain cell lines that are sensitive to alcohol), sterile water for injection or phosphate-buffered saline (PBS, pH 7.4) may be used, but these formulations should be prepared as single-use aliquots and not stored beyond 24 hours at 4 °C.

A practical reconstitution protocol for a 10 mg vial: swab the vial septum with 70% isopropanol and allow to dry. Draw up 2.0 mL of bacteriostatic water in a 3 mL syringe fitted with a 23-gauge needle. Direct the diluent stream against the inside wall of the vial rather than directly onto the lyophilized cake to minimize foaming. Gently swirl (do not vortex) until the cake dissolves completely, typically within 30-60 seconds. This yields a stock concentration of 5 mg/mL (5000 µg/mL). Further dilution in sterile saline or PBS to working concentrations of 100-500 µg/mL is standard for subcutaneous injection experiments in rodents. See our complete reconstitution guide for full step-by-step instructions with photographs.

Research Dose Calculations: Worked Examples

Example 1 (rat subcutaneous injection, 100 nmol/kg): The molecular weight of Ipamorelin is 711.87 g/mol, so 1 nmol = 0.71187 µg. For a 100 nmol/kg dose in a 250 g rat: dose = 100 nmol/kg × 0.25 kg × 0.71187 µg/nmol = 17.8 µg per injection. Using a stock solution of 100 µg/mL, inject 0.178 mL (approximately 180 µL). This is within the standard acceptable subcutaneous injection volume for rats (up to 500 µL per site).

Example 2 (rat subcutaneous injection, 300 nmol/kg): For the same 250 g rat at the highest dose used in the Johansen 1999 study: 300 nmol/kg × 0.25 kg × 0.71187 µg/nmol = 53.4 µg. Using the same 100 µg/mL stock, inject 0.534 mL (approximately 535 µL), at or near the upper limit; splitting across two sites is preferable at this volume in small rodents.

Example 3 (in vitro cell culture, 10 nM working concentration): For a primary rat pituitary cell assay requiring 10 nM Ipamorelin in 1 mL per well: 10 nM × 1 mL = 10 pmol = 7.12 ng in the well. From a 100 µg/mL stock, dilute 1:14,085 in assay buffer, practically achieved by two serial dilutions (1:100 then 1:141) to maintain pipetting accuracy. Prepare freshly before each assay run; do not pre-dilute to nanomolar concentrations more than 2 hours before use, as adsorption to polypropylene surfaces and dilution-driven instability can reduce effective concentration.

For additional worked examples and a detailed dose-conversion table covering multiple species and molar dose levels, see our dosage calculation guide.

Side Effects and Safety

Preclinical Safety Observations

The preclinical safety data for Ipamorelin is limited in scope but internally consistent across published studies. In the original Raun 1998 study, no acute adverse events were observed in rats receiving intravenous doses up to 100 nmol/kg, and gross behavior was unremarkable over the 2-hour observation period. ^[1] The 12-week chronic dosing study by Svensson 2000 reported no treatment-related mortality, no changes in organ weights at necropsy (liver, kidney, heart, spleen, and adrenals were evaluated), and no histopathological abnormalities in pituitary or hypothalamic tissue at the 40 nmol/kg/day infusion dose. ^[12]

Cardiovascular parameters were not formally monitored in most published studies. Ghrelin receptor agonism is associated with positive chronotropic and inotropic effects in isolated heart preparations and with modulation of autonomic tone in conscious animals, mediated partly through cardiac GHS-R1a expression. ^[11] Whether Ipamorelin at research doses produces measurable hemodynamic effects has not been formally characterized in a dedicated cardiovascular safety study; this is a recognized gap in the preclinical safety dossier.

Hormonal Side-Effect Profile

The most directly characterized safety-relevant property of Ipamorelin is its selective hormonal profile. Multiple studies confirm that, at doses producing robust GH secretory responses, Ipamorelin does not significantly stimulate ACTH, cortisol, prolactin, FSH, LH, or TSH in rat models. ^{[1] [2]} This selective profile is pharmacologically favorable for research purposes because it allows attribution of downstream effects (bone density, body composition, metabolism) to GH/IGF-1 signaling rather than to confounding adrenocortical or gonadal hormone changes.

The single published human pharmacology study confirms that ACTH, cortisol, and prolactin remain at baseline levels following single IV doses up to 10 µg/kg, consistent with preclinical selectivity data. ^[13] Whether higher doses or chronic repeated dosing in humans would preserve this selectivity is unknown; no long-term human safety studies have been published.

Tachyphylaxis and Receptor Desensitization

As discussed in the Andersen 2001 study, high-frequency repeated dosing in rats produces receptor desensitization with attenuation of GH response. ^[14] This is consistent with the general biology of GPCR desensitization through beta-arrestin recruitment and receptor internalization. From a safety standpoint, desensitization limits the duration of effect but does not imply toxicity; from a research design standpoint, it means that studies using very frequent dosing schedules will encounter diminishing GH signals over time, potentially invalidating dose-response assumptions made at study initiation.

Potential Concerns at Higher Research Doses

At suprapharmacological concentrations in vitro (above 1 µM), Ipamorelin has not been systematically tested for cytotoxicity in published literature. Researchers using very high concentrations in cell-based assays should include vehicle and high-dose peptide cytotoxicity controls (MTT assay or equivalent) as standard practice. No published data on mutagenicity, genotoxicity, reproductive toxicity, or carcinogenicity for Ipamorelin exist in the peer-reviewed literature, reflecting the early-stage nature of its preclinical characterization.

How It Compares

The comparative landscape of GHSs illustrates where Ipamorelin sits in terms of research utility. Its primary advantage over GHRP-6 and GHRP-2 is the absence of cortisol and prolactin co-secretion, which simplifies experimental interpretation. ^[2] Hexarelin produces larger GH pulses in comparative studies but with a substantially more complex hormonal response that compromises its utility as a selective probe. ^[16]

Macimorelin, the only FDA-approved GHS-R1a agonist (approved 2017 for diagnostic use in adult growth hormone deficiency), provides a relevant clinical benchmark. ^[17] Its oral bioavailability, longer half-life, and regulatory approval set it apart from Ipamorelin, but its approved indication is strictly diagnostic (single-dose stimulation testing), not therapeutic, and its approved dose is substantially lower than doses used in experimental research protocols for body composition or bone endpoints. Researchers exploring GHS-R1a pharmacology in translational contexts frequently use macimorelin's approval profile as a comparator when discussing what would be required to advance an experimental compound.

Sermorelin acts through an entirely different receptor (GHRHR rather than GHS-R1a) and thus does not compete directly with Ipamorelin as a pharmacological probe for GHS-R1a biology, though both increase GH secretion and downstream IGF-1. The mechanistic distinction is useful for studies attempting to dissect the relative contributions of GHRH-R and GHS-R1a to pulsatile GH regulation.

MK-677 (ibutamoren) offers oral bioavailability and a prolonged 24-hour half-life in humans, features that Ipamorelin lacks, making it better suited for chronic dosing paradigms. ^[18] However, its non-peptide structure and different binding mode within GHS-R1a may produce distinct downstream signaling compared to Ipamorelin, a difference that has not been thoroughly characterized in head-to-head signaling studies.

Where to Buy

Apollo Peptide Sciences supplies this product under the slug ipamorelin-2, with a vial specification of 10 mg at $70.00. For full vendor evaluation criteria including CoA documentation standards, third-party testing history, and cold-chain shipping practices, see our peptide supplier guide.

Our internal review for this specific product is available at Ipamorelin 10mg, Apollo Peptide Sciences. The product page includes the most current lot-specific CoA data, verified HPLC trace screenshots, and mass spectrometry identity confirmation where available.

When evaluating any GHS research peptide vendor, the minimum acceptable documentation standard is: HPLC purity trace with lot number, mass spectrometry molecular identity confirmation, and endotoxin test result. Vendors that provide only HPLC purity without mass spectrometry confirmation should be regarded cautiously for critical experimental applications. Our supplier evaluation guide provides a structured scoring rubric for comparing vendors across these criteria.

Open Research Questions

Several important questions about Ipamorelin's pharmacology remain unresolved in the published literature, creating both limitations for current research programs and opportunities for future investigation.

The translational gap between rodent and human pharmacology is the most pressing unresolved issue. The Nass 2008 study provides a single-dose, intravenous-only snapshot of GH response in young adults, but no published data address chronic subcutaneous dosing in humans, effects in elderly or GH-deficient populations, or long-term safety in any human cohort. ^[13] This gap is substantial relative to the compound's profile in vendor literature, which sometimes implies a more complete human evidence base than actually exists.

Biased agonism at GHS-R1a is a mechanistic question that has not been addressed for Ipamorelin. Ghrelin itself shows evidence of biased signaling, preferentially activating Gq over Gs pathways under some conditions, and different synthetic ligands at the same GPCR may produce distinct signaling fingerprints with potentially different physiological outcomes. Whether Ipamorelin's apparent selectivity for GH secretion over cortisol/prolactin is explained by biased agonism (differential pathway activation) or by lower intrinsic efficacy at cortisol-relevant signaling cascades is not resolved.

The role of peripheral GHS-R1a in mediating effects beyond GH secretion has not been systematically studied for Ipamorelin. Ghrelin's cardioprotective, orexigenic, and neuroprotective effects involve GHS-R1a in peripheral and central non-pituitary locations; whether Ipamorelin recapitulates these effects (and at what doses) is an open question with implications for its utility as a research tool in those fields.

Finally, the interaction between Ipamorelin and the endogenous ghrelin system under conditions of altered nutritional state has not been characterized. Ghrelin levels rise with fasting and fall postprandially, and GHS-R1a responsiveness may vary with nutritional status; studies using Ipamorelin across fed/fasted conditions and in models of metabolic disease would substantially expand its research utility and translational relevance.

FAQ